As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: July 20, 2014
by University of Barcelona:
Researchers at the University of Barcelona (UB) and the Institute for Bioengineering of Catalonia (IBEC), together with members of the CIBERNED at the Centre for Molecular Biology in Madrid, and the Institute of Neuropathology of IDIBELL – Bellvitge University Hospital, reveal that our nervous system’s naturally protective response to the onset of Alzheimer’s may contribute to the fact that patients do not suffer memory loss until the disease has progressed further. The study has been published in the journalMolecular Neurobiology.
Alzheimer’s is a neurodegenerative disease characterized by a gradual loss of memory and other mental dysfunction, as neurons die and different areas of the brain atrophy. The disease is the most common form of dementia and appears most frequently in people over 65.
There are two stages: the initial one where symptoms aren’t clear, and a second phase with well-defined symptoms. Alzheimer’s can be attributed to two major events that can happen in the brain: the presence of extracellular aggregates, mostly a compound known as beta-amyloid peptide, which forms plaques; and the accumulation of a very phosphorylated form of the protein tau, which forms small tangles inside affected neurons.
Researchers describe the relationship between beta-amyloid peptide oligomers and tau phosphorylation and the presence of another protein, the cellular prion protein (PrPc), in affected neurons. “Previous studies had looked at the levels of PrPc in advanced stages of the disease”, explains Dr José Antonio del Río, leader of the Molecular and Cellular Neurobiotechnology Research Group at IBEC and professor from the Department of Cellular Biology at UB.
“Our new study —he points out— shows, both in mice and human brains affected by Alzheimer’s, an increase in protein PrPc during the early, asymptomatic stages of the disease. However, these levels of PrPc decrease as the disease progresses”. “As a result, it is reasonable to draw the conclusion that the overexpression of PrPc seen at the beginning of the disease is part of the protective response of the nervous system in an attempt to suppress the progress of Alzheimer’s”, concludes Dr del Río.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.